Clinical Trial Update: A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206) [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial evaluating the safety and tolerability of Pumitamig alone or in combination with ipilimumab in first-line advanced or unresectable hepatocellul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Pumitamig
• ipilimumab (ipilimumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Hepatocellular Carcinoma (HCC) | Phase 1, Phase 2 | Status: RECRUITING